Medical Devices Pick: CombiMatrix
Posted in Healthcare Stocks on September 29th, 2008Our special focus this week at TWST is on Medical Devices. We spoke with analyst John Putnam of Dawson James Securities a little bit about what he sees as the strongest players in this space right now.
Putnam’s pick is a company called CombiMatrix (CBMX), what he describes as a “leading company in doing genetic testing.” Here’s what he had to say the main appeal of CombiMatrix was:
”CombiMatrix has a prenatal test that can replace the old test, an amniocentesis to test primarily for Down Syndrome. There are more than 100 abnormalities that a fetus can have and CombiMatrix has a single test that identifies all of them as compared to just four or five that a normal amniocentesis would do, with the cost being the same. So the information gained from that kind of a test is so much greater than what we used to have that you really have a good idea of whether the child is going to be normal or not.”
Putnam sees CombiMatrix as a good company to play in this space. The reason is that the way they makes these tests, they are allowed to put products on the market without needing to go to the FDA, whereas its competitors are forced to. They have been able to put a new test out every quarter for the last six quarters- far exceeding their competitors.
For the complete interview with Mr. Putnam- including an overview of the state of this space in general, where its heading and more stock picks, click here.
O, had agreed to step down by year’s end. McGrath had been in his position for three years. Unisys and particularly McGrath have been under intense pressure from shareholders to make major changes at the firm.
The company has been languishing for sometime now and has seen a decline in revenue over the last few years. Special pressure has been applied by MMI Investments LLP, an activist shareholder who owns over 9% of the firm. Back in January of 2008, MMI wrote an angry letter to Unisys management. A portion of the
pressure for sometime now. Many analysts and others (
The board named James Marcom, a current member of the board, as the acting president and CEO. He joined the board back in June. He is an ally of Wattles and was originally nominated by Wattles to become a member of the board. The board also appointed Allen B. King as the new chairman. According to a story by Ylan Q. Mui of the
day, a 38 year veteran of the firm and the company’s CEO for the last ten years, will be stepping down as of January 1. The board announced that Holliday will be replaced at the time by Ellen Kullman. Kullman currently is an executive vice president and a member of Dupont’s office of the chief executive. She has been with the firm since 1988. According to Reuters,